Meditope Biosciences, Inc., a biotechnology company developing antibody-based products using its proprietary monoclonal antibody (mAb) technology platform, today announced receiving its first patent, U.S. Patent No. 8,658,774, entitled “Novel Meditopes and Related Meditope-Monoclonal Antibody Delivery Systems, Synthesis and Therapeutic Uses Thereof.”
“We view the issuance of this patent, about two years from initial filing, as validation of the novelty of our platform and an important step in our strategy to build and protect a strong and highly differentiated antibody technology,” explained Stephanie Hsieh, Meditope’s president and chief executive officer.
“Antibody-drug conjugates or ADCs. are an area of significant opportunity in drug development and we look forward to leveraging our unique technology to address the industry’s needs.”
Published in: Meditope Biosciences, Inc. website